Statins induce lethal effects in acute myeloblastic lymphoma cells within 72 hours

Leukemia and Lymphoma

Volumn 49, Issue 2, 2008, Pages 322-330

  Burke, Lillian P ^a   Kukoly, Cynthia A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Drug studies; HL60 cells; HMG CoA reductase inhibitors; Leukemic cell lines; Statins; U937 cells

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL STRAIN HL 60; CELL STRAIN U937; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; PRIORITY JOURNAL; REACTION TIME; SENSITIVITY ANALYSIS;

APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKEMIA, MYELOID, ACUTE; LOVASTATIN; MEVALONIC ACID;

EID: 38849127391     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701760011     Document Type: Article

References (30)

1. Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J. and White, C. M. (2006) Statins and cancer risk: A meta-analysis. JAMA, 295, pp. 74-80.
2. Poynter, J. N., Gruber, S. B., Higgins, P. D., Almog, R., Bonner, J. D. and Rennert, H. S. (2005) HMG CoA reductase inhibitors and the risk of colorectal cancer. N Engl J Med, 352, pp. 2184-2192.
3. Chan, K KW, Oza, A. M. and Siu, L. L. (2003) The statins as anticancer agents. Clin Cancer Res, 9, pp. 10-19.
4. Maksumova, L., Ohnishi, K., Muratkhodjaev, F., Zhang, W., Pan, L. and Takeshita, A. (2000) Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia, 14, pp. 1444-1450.
5. Dimitroulakos, J., Nohynek, D., Backway, K. L., Hedley, D. W., Yeger, H. and Freedman, M. H. (1999) Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood, 93, pp. 1308-1318.
6. Hunakova, L., Sedlak, J., Sulikova, M., Chovancova, J., Duraj, J. and Chorvath, B. (1997) Human multidrug-resistant myeloid leukemia HL-60/ADR cells in vitro: Resistance to the mevalonate pathway inhibitor lovastatin. Neoplasia, 44, pp. 366-369.
7. Diamond, A. M., Jaffe, D., Murray, J. L., Safa, A. R., Samuels, B. L. and Hatfield, D. L. (1996) Lovastatin effects on human breast carcinoma cells. Differential toxicity of an adriamycin-resistant derivative and influence on selenocysteine tRNAS. Biochem Mol Biol Int, 38, pp. 345-355.
8. Pallis, M., Turzanski, J., Higashi, Y. and Russell, N. (2002) P-glycoprotein in acute myeloid leukaemia: Therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma, 43, pp. 1221-1228.
9. Dimitroulakos, J. and Yeger, H. (1996) HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med, 2, pp. 326-333.
10. Grundy, S. M., Cleeman, J. I., Merz, C. N., Brewer Jr, H. B., Clark, L. T. and Hunninghake, D. B. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol, 44, pp. 720-732.
11. Wong, W. W., Dimitroulakos, J., Minden, M. D. and Penn, L. Z. (2002) HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia, 16, pp. 508-519.
12. Xia, Z., Tan, M. M., Wong, W. W., Dimitroulakos, J., Minden, M. D. and Penn, L. Z. (2001) Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia, 15, pp. 1398-1407.
13. Stirewalt, D. L., Appelbaum, F. R., Willman, C. L., Zager, R. A. and Banker, D. E. (2003) Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res, 27, pp. 133-145.
14. Scheffold, C., Schottker, B., Lefterova, P., Csipai, M., Glasmacher, A. and Huhn, D. (2000) Increased sensitivity of myeloid leukemia cell lines: Potential of lovastatin as bone-marrow-purging agent. Acta Haematol, 104, pp. 72-79.
15. Walsh, K. M., Albassam, M. A. and Clarke, D. E. (1996) Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs. Toxicol Pathol, 24, pp. 468-476.
16. Holstein, S. A., Knapp, H. R., Clamon, G. H., Murry, D. J. and Hohl, R. J. (2006) Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol, 57, pp. 155-164.
17. Walsh, K. M. and Rothwell, C. E. (1999) Hepatic effects in beagle dogs administered atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, for 2 years. Toxicol Pathol, 27, pp. 395-401.
18. Thibault, A., Samid, D., Tompkins, A. C., Figg, W. D., Cooper, M. R. and Hohl, R. J. (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res, 2, pp. 483-491.
19. Knox, J. J., Siu, L. L., Chen, E., Dimitroulakos, J., Kamel-Reid, S. and Moore, M. J. (2005) A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer, 41, pp. 523-530.
20. Hancock, J. F. (1995) Prenylation and palmitoylation analysis. Methods Enzymol, 255, pp. 237-245.
21. Dimitroulakos, J., Thai, S., Wasfy, G. H., Hedley, D. W., Minden, M. D. and Penn, L. Z. (2000) Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma, 40, pp. 167-178.
22. Maltese, W. A., Sheridan, K. M., Repko, E. M. and Erdman, R. A. (1990) Post-translational modification of low molecular mass GTP-binding proteins by isoprenoid. J Biol Chem, 265, pp. 2148-2155.
23. Clutterbuck, R. D., Millar, B. C., Powles, R. L., Newman, A., Catovsky, D. and Jarman, M. (1998) Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol, 102, pp. 522-557.
24. Li, H. Y., Appelbaum, F. R., Willman, C. L., Zager, R. A. and Banker, D. E. (2003) Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood, 101, pp. 3628-3634.
25. van der Spek, E., Bloem, A. C., van de Donk, N. W., Bogers, L. H., van der Griend, R. and Kramer, M. H. (2006) Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica, 91, pp. 542-545.
26. Zhong, W. B., Wang, C. Y., Chang, T. C. and Lee, W. S. (2003) Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology, 144, pp. 3852-3859.
27. Holmberg, M., Sandberg, C., Nygren, P. and Larsson, R. (1994) Effects of lovastatin on a human myeloma cell line: Increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anticancer Drugs, 5, pp. 598-600.
28. Kornblau, S. M., Banker, D. E., Stirewalt, D., Shen, D., Lemker, E. and Verstovsek, S. (2007) Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin+high-dose Ara-C: A phase 1 study. Blood, 109, pp. 2999-3006.
29. Holstein, S. A. and Hohl, R. J. (2001) Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk Res, 25, pp. 651-660.
30. Lishner, M., Bar-Sef, A., Elis, A. and Fabian, I. (2001) Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med, 49, pp. 319-324.